Organon & Co.
NYSE:OGNDrug Manufacturers - General
+$0.01 today
- Market cap
- $3.66B
- Beta
- 1.54
- P/E (TTM)
- 14.2
- EPS (TTM)
- $0.94
- Dividend yield
- 0.60%
Volume 3.90M
Average 8.57M
OGN Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Organon & Co.NYSE: OGN
Net Margin · Q3 FY2026 · quarter ended Sep 2026
Net margin holds steady near 10.4%
Net margin was 10.4% in Q3 FY2026, up 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 3.5%, down 4.5 pp year over year. Over 3 fiscal years it narrowed by 11.8 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 2 analysts of 14.3% for the fiscal year ending Dec 2026, up from 3.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 10.4%+3.5 pp QoQ
- Last fiscal yearDec 2025
- 3.0%-10.5 pp YoY
- LTMSep 2026
- 3.5%-4.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.4 pp | +27.3 pp | +26.9 pp |
| 1 year | -10.5 pp | +11.3 pp | +21.7 pp |
| 3 years | -11.8 pp | +12.6 pp | +24.4 pp |
| 5 years | +12.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 3.0%
- Year-over-year change
- -10.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.0% | -10.5pp |
| FY2024 | 2024-12-31 | 13.5% | -2.8pp |
| FY2023 | 2023-12-31 | 16.3% | +1.5pp |
| FY2022 | 2022-12-31 | 14.9% | -6.6pp |
| FY2021 | 2021-12-31 | 21.4% | — |
Net Margin vs competitors
How OGN compares with its peers on the latest reported figures
- OGN's LTM Sep 2026 net margin of 3.5% is the 6th highest of the 10 companies compared; the peer median is 4.5%.
- Its year-over-year change of -4.5 pp is the 7th highest of 10, against a peer median of -0.8 pp.
- Over three fiscal years its change of -11.8 pp compares with a peer median of -0.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 100.8% | +77.5 pp | +182.2 pp | |
| LTM Jun 2026 | 18.9% | -4.5 pp | -23.2 pp | |
| LTM Sep 2026 | 7.7% | -0.8 pp | +5.3 pp | |
| LTM Mar 2026 | 6.3% | +3.7 pp | -1.5 pp | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | 4.5% | +10.7 pp | -0.5 pp |
| LTM Sep 2026 | 3.5% | -4.5 pp | -11.8 pp | |
| LTM Mar 2026 | 2.4% | -1.6 pp | +0.2 pp | |
| LTM Mar 2026 | -14.4% | -30.9 pp | +623.3 pp | |
| LTM Jun 2026 | -88.2% | +1325.2 pp | — | |
| LTM Feb 2026 | -156.2% | -37.9 pp | -190.4 pp | |
| Peer median (excluding OGN) | 4.5% | -0.8 pp | -0.2 pp | |
Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.3B | 6.17B | 6.26B | 6.4B | 6.22B |
| Cost of Revenue | 2.38B | 2.29B | 2.52B | 2.69B | 2.85B |
| Gross Profit | 3.92B | 3.88B | 3.75B | 3.72B | 3.36B |
| Gross Margin | 62.2% | 62.8% | 59.8% | 58.0% | 54.1% |
| Research & Development | 443M | 471M | 528M | 469M | 366M |
| Selling, General & Admin | 1.67B | 1.7B | 1.89B | 1.76B | 1.71B |
| Operating Expenses | 2.01B | 2.18B | 2.42B | 2.23B | 2.09B |
| Depreciation & Amortization | 195M | 212M | 236M | 277M | 361M |
| EBITDA | 1.98B | 1.76B | 1.44B | 1.6B | 1.29B |
| EBITDA Margin | 31.4% | 28.4% | 22.9% | 25.1% | 20.8% |
| Operating Income | 1.92B | 1.71B | 1.33B | 1.49B | 1.29B |
| Operating Margin | 30.4% | 27.6% | 21.2% | 23.2% | 20.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 258M | 422M | 527M | 520M | 504M |
| Other Income / Expenses | (386M) | (583M) | (654M) | (679M) | (860M) |
| Income Before Tax | 1.53B | 1.12B | 673M | 807M | 425M |
| Pre-Tax Margin | 24.3% | 18.2% | 10.7% | 12.6% | 6.8% |
| Income Tax Expense | 178M | 205M | (350M) | (57M) | 238M |
| Net Income | 1.35B | 917M | 1.02B | 864M | 187M |
| Net Margin | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
| EPS (Basic) | 5.33 | 3.61 | 4.01 | 3.36 | 0.72 |
| EPS (Diluted) | 5.33 | 3.59 | 3.99 | 3.33 | 0.72 |
| Weighted Avg Shares | 253.55M | 254.08M | 255.24M | 257.05M | 259.5M |
| Weighted Avg Shares (Diluted) | 253.55M | 255.17M | 256.27M | 259.15M | 260.76M |
Organon & Co.
NYSE:OGN
Intrinsic Alpha fair value
Locked
Current Price
$13.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.